Biopharma
Biopharma Leaders Navigate AI ‘Hype Cycle’: Bayer, Daiichi Sankyo, and argenx Share Insights on AI Implementation in Marketing
AI in biopharma marketing, Bayer, Daiichi Sankyo, argenx, AI implementation, biopharma industry, AI hype cycle
Roche Secures FDA Approval for Subcutaneous Ocrevus and Tecentriq, Lilly Gains Approval for Eczema Treatment
FDA approvals, Roche, Subcutaneous products, Ocrevus, Tecentriq, Lilly, Eczema treatment, Pharmaceutical industry, Biopharma news
Charles River Laboratories Reduces Workforce by 3% Amid Q2 Revenue Decline
Charles River Laboratories, workforce reduction, layoffs, Q2 revenue drop, biopharma industry, restructuring initiatives
BridgeBio Unveils GondolaBio with $300M Investment, Transfers Key Programs to Joint Venture
BridgeBio, GondolaBio, Joint Venture, $300M Investment, Genetic Therapies, Biopharma Startup
Evotec Announces Restructuring Plan Amid Research Spending Slowdown
Evotec, layoffs, restructuring, research spending slowdown, gene therapy, biopharma
Aeterna Zentaris Rebrands as COSCIENS Biopharma: A New Era in Biopharmaceuticals
Aeterna Zentaris, COSCIENS Biopharma, biopharmaceuticals, rebranding, name change, therapeutic development, diagnostic tests, Macrilen, adult growth hormone deficiency
Pharma Campaign Contributions, Vaccine Hiccups, and Lykos’ Moment of Truth
Pharma campaign contributions, vaccine hiccups, Lykos Therapeutics, MDMA-assisted treatment, FDA approvals, Q2 earnings, biopharma challenges
Sangamo Partners with Genentech for $1.9 Billion Neurology-Focused Deal Using Zinc Finger Technology
Sangamo, Genentech, zinc finger technology, neurology, Alzheimer’s disease, tau gene, biobucks, biopharma, gene therapy, Fabry disease
Biopharma Companies uniQure and Arbutus Announce Workforce Reductions to Focus on Priority Programs
uniQure, Arbutus Biopharma, layoffs, workforce reduction, biopharma, priority programs, gene therapy, clinical trials
Biosecure Lawmakers Target China Studies in New Regulatory Push
Biosecure Act, China studies, clinical trials, biopharma, U.S.-China relations, drug production, national security, pharmaceutical supply chain